La salud en Italia:
We live in an age of unprecedented medical innovation. Unfortunately, most of today's cutting-edge research is conducted outside Europe, which was once a pioneer in this field. About 78% of global biotechnology research funds are spent in the U.S., compared to just 16% in Europe. Americans therefore have better access to modern drugs. One result is that in the U.S., the annual death rate from cancer is 196 per 100,000 people, compared to 235 in Britain, 244 in France, 270 in Italy and 273 in Germany.
It is both a tragedy and an embarrassment that Europe hasn't kept up with the U.S. in saving and improving lives. What's to blame? The Continent's misguided policies and state-run health-care systems. The reasons vary from country to country, but broadly speaking, the custodians of public health budgets aren't devoting the necessary resources to get patients the most modern and advanced medicines, and are happier with the status quo.
Muy relacionado con el tema, mira esto que publicaba hace unos días.
ReplyDeleteThe difference in the mortality rate maybe associated with the effort of the U.S. to invest in research and technology.
ReplyDeleteArmand Rousso
http://biotechnology.armandrousso.biz/
Armand, I am sure it is related. The US generates the bulk of all medical advances in the world, including new drugs and technologies.
ReplyDelete